Navigation Links
Cytonus Therapeutics Announces Christopher Thorne as Chairman
Date:1/27/2020

Cytonus Therapeutics Inc. today announced the appointment of Christopher Thorne as Chairman. Thorne is a noted investor, tech entrepreneur, and former senior management consultant at McKinsey & Company who holds three Harvard degrees. He serves as Executive Chairman of Broadline Capital, the global alternative investment firm.

“Chris Thorne has exceptional business acumen with a proven track record in developing purpose-led businesses, driving innovation, and reinforcing a commitment to corporate responsibility,” commented Cytonus’ Founder and CEO, Remo Moomiaie-Qajar, MD. “He has extensive directorship experience at both publicly-listed corporations and privately-held ventures, as well as 501(c)(3) nonprofit organizations. All of these attributes, combined with his excellent people engagement and strategic insight, gives us confidence that Chris will help build a strong culture as we work together toward our shared vision for the Company and accelerate the development of our innovative platform of products to improve the health and lives of people across the globe.”

“Cytonus is delighted to have appointed Chris Thorne as our Chairman after a thorough and rigorous selection process,” commented Cytonus’ Founder and Chief Scientific Officer, Richard Klemke, PhD. “Chris is an outstanding leader who brings vast experience across multiple industries, from his career at McKinsey & Company, to his accomplishments as a visionary entrepreneur, and his success as an astute investor.”

Mr. Thorne will lead Cytonus’ corporate board of directors and will serve as an independent non-executive director for the company.

About Cytonus Therapeutics Inc.

Cytonus Therapeutics Inc. is the cell-based platform technology company whose next-generation Adoptive Cellular Therapy (ACT) technologies have a wide range of medical applications across multiple therapeutic areas. Cytonus is developing a vast platform of proprietary immunotherapeutic products to cure a wide range of medical conditions including difficult-to-treat cancers and inflammatory diseases, and to improve patient outcomes. Its portfolio of inventions addresses the recognized limitations of existing cell-based therapies. Its proprietary pipeline of Cargocyte™ technologies are cellular-engineered enucleated transporters of a multiplicity of therapeutic payloads to tissue in selective, potent, and controllable off-the-shelf cellular therapies for treating numerous targeted diseases. Cytonus’ new category-creating technologies are expected to transform how cancers and other diseases will be treated in the future and have the potential to improve the health and lives of millions of people around the world. For more information, please visit the Cytonus website at https://Cytonus.com and follow our LinkedIn and Twitter feeds at: @Cytonus.

Statements in this news release relating to Cytonus’ plans and strategies, new and existing products and technologies, anticipated clinical and regulatory pathways, and markets for its products, are forward-looking statements. The words "believe," "expect," "anticipate," "estimate," "project," and similar expressions identify forward-looking statements that speak only as of the date hereof. Such statements involve risks and uncertainties that could cause actual results to differ materially from anticipated results due to many factors, including regulatory and development risks. Cytonus undertakes no obligation to publicly update or revise any forward-looking statements. This news release is neither an offer to sell, nor the solicitation of any offer to purchase, any security.

Follow Cytonus on LinkedIn and Twitter at: @Cytonus.

Read the full story at https://www.prweb.com/releases/cytonus_therapeutics_announces_christopher_thorne_as_chairman/prweb16858313.htm.


'/>"/>
Source: PRWeb
Copyright©2020 Vocus, Inc.
All rights reserved


Related biology news :

1. Drug development venture links translational research, business to launch new therapeutics
2. Trovagene Announces Abstracts to be Presented at Molecular Targets and Cancer Therapeutics Conference
3. Arcturus Therapeutics Raises $5 Million in Series A Funding to Maintain its Momentum in Nominating Lead Clinical Candidate in 2014
4. Natura Therapeutics product shown to improve decision making skills in older adults
5. Emerging class of therapeutics represents a coming wave for developers and manufacturers
6. FASEB announces 2014 SRC: Translational Neuroimmunology: From Mechanisms to Therapeutics
7. Next-generation glaucoma therapeutics hold considerable promise
8. Nanomerics, UCL, H Lundbeck & Exeter University to research new brain therapeutics
9. Industry group release testing recommendations for oligonucleotide-based therapeutics
10. Splice-switching oligonucleotide therapeutics is new method for editing gene transcript
11. Human Longevity, Inc. and Celgene Cellular Therapeutics Sign License Agreement to Develop and Commercialize Placental Stem Cell Population, PSC-100 for Multiple Therapeutic Applications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/20/2020)... ... March 20, 2020 , ... ... human embryonic stem cell (ESC) derived mesenchymal stem cells (hES-MSC), through a proprietary ... treatment of neurological, autoimmune, and rare orphan diseases, today announced that the U.S. ...
(Date:3/13/2020)... , ... March 13, 2020 , ... ... the lifespan of stored cord blood performed by Dr. Hal Boxmeyer and colleagues, ... storage time for cryogenically preserved cells under proper conditions. Cryo-Cell International marks the ...
(Date:3/11/2020)... ... March 11, 2020 , ... USARAD Holdings ... Siemens Healthineers and several healthcare VC firms introduces a first of its kind ... 100 countries and has caused over 4,000 fatalities to date. Over the years, ...
Breaking Biology News(10 mins):
(Date:3/19/2020)... ... March 18, 2020 , ... Family ... signals to provide rapid insight into their perceptions of events. Imagine if a ... other. What if they could measure the level of engagement of each individual ...
(Date:3/10/2020)... , ... March 10, 2020 , ... Lifecycle Biotechnologies ... 13 acres in Cleburne, Texas to be used as a biopharmaceutical and biotechnology production ... headquarters and sales offices as well as its production and development hub. The company ...
(Date:3/2/2020)... ... 2020 , ... McBee, Moore and Vanik IP, LLC (MMV IP) has been ... and Organics. , According to statistics compiled by Harrity Anaytics, MMV IP was listed ... center 1600 during 2019. Technology center 1600 at the US Patent Office (“USPTO”) specializes ...
(Date:2/21/2020)... ... February 20, 2020 , ... The dietary supplement ... consumers that what’s listed on an ingredient panel is actually in their product. ... solution with the adoption of CertainT, which is designed to protect the intellectual ...
Breaking Biology Technology: